DOSAGE INDEX / SINGLE
Melanotan II
Research, reported schedules and supply planning.
Examine Melanotan II tanning and erectile-response studies, serious safety reports, product identity and the limits of early human evidence.
Source: PeptideDosages.com. Independently written summaries of reported protocols, not validated treatment recommendations. Reviewed for transcription on September 21, 2026.
Research Protocol & Dosage
Source-reported examples · not treatment recommendations
- Amount
- 250–1,000 micrograms per day; later examples use 500–1,000 micrograms per administration
- Frequency
- Daily initially, then once or twice weekly
- Cycle / observation period
- 6–8 weeks initially
- Route / research model
- Subcutaneous
The source also names a 200-microgram starting option. This is not an approved-product dosing summary.
Titration & progression
A dose range is not a titration schedule. No independently verified stepwise escalation has been established for this source-reported regimen.
Supply & Planning
Compare vial strengths here. A different vial size changes the available material, not the biological dose.
Diluent & formulation
Diluent compatibility is formulation-specific. A verified manufacturer instruction is still needed before bacteriostatic water or another diluent can be listed as suitable for this research material.
Vial comparison
No single complete schedule is resolved for this entry. Enter a documented total to compare strengths; the calculator does not select a regimen.
| Vial strength | Vials needed |
|---|---|
| 10 mg | Enter a total |
Enter a positive material total.
Material minimum only: round total material ÷ vial content up to a whole vial. Actual supply may be higher because of single-use packaging, discard dates, dead space or losses. No validated multi-use storage period is assumed.
Reported Research Results
Selected observations from the cited research. Each finding retains its study population, formulation and limitations.
- The original phase I publication describes Melanotan II, also abbreviated MT-II, as a synthetic cyclic melanotropic peptide based on an alpha-melanocyte-stimulating-hormone fragment. The study investigated its pigmentation activity and observed effects beyond skin color. [1]
- In the 1996 pilot, two of the three volunteers developed increased pigmentation. Reported effects included nausea, spontaneous erections and, at a higher exposure, somnolence and fatigue in one participant. The study used injected research material with placebo comparison. [1]
- The double-blind crossover study enrolled ten men with erectile dysfunction without a known organic cause. Clinically apparent erections occurred in eight after Melanotan II. The reported mean duration of high tip rigidity was 38 minutes with Melanotan II and three minutes with placebo. Nausea, yawning, stretching and reduced appetite occurred more often with the active compound. [2]
Sourcing & Vendor Information
No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.
Sources & Further Reading
Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.
Bibliography checked September 22, 2026: 10 entries mapped from 1 source page. Medical and supporting references are retained below; supplier entries are excluded.
- Original identity and clinical report
- Original 1998 trial
- DermNet NZ — Melanotan II Information for PatientsFurther reading · Listed in reference bibliography.
- PubMed — Nelson ME et al. (2012)Further reading · Listed in reference bibliography.
- RxList — Melanotan-II Uses, Side Effects and DosingFurther reading · Listed in reference bibliography.
- Health Service Executive (HSE) IrelandNo destination link supplied in the source bibliography.Further reading · Listed in reference bibliography.
- NCBI Bookshelf — Administration of Parenteral MedicationsFurther reading · Listed in reference bibliography.
- CDC — Vaccine Administration GuidelinesGeneral guidance · Listed in reference bibliography.
- NCBI Bookshelf — Best Practices for Injection SafetyFurther reading · Listed in reference bibliography.
- MedlinePlus — Subcutaneous InjectionsGeneral guidance · Listed in reference bibliography.
Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.